Corcept Therapeutics: Discounted Biotech Company Offers Exceptional Risk Profile And Lucrative Proprietary Pipeline
January 22, 2019 at 03:08 AM EST
Corcept is a rare low-risk/high-reward investment opportunity in the Biotechnology industry. Total 2018 revenues of $250-270 million represent 90% CAGR over the past 5 years. DCF and comp analysis indicate shares are currently discounted by 35%.